Zongertinib Granted Accelerated Approval in Nonsquamous NSCLC for HER2 TKD-Activating Mutations
Zongertinib gains FDA approval for treating HER2-mutated non–small cell lung cancer (NSCLC), offering hope with fewer side effects and promising response rates in patients.